about
Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.Biomarkers of the immunomodulatory effect of immunosuppressive drugs in transplant recipients.Simultaneous pancreas-kidney transplantation in HIV-infected patients: a case report and literature review.Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.Renal transplantation in HIV-infected patients: 2010 update.Antimicrobial and immunosuppressive drug interactions in solid organ transplant recipients.Cytokines as predictive biomarkers of alloreactivity.Renal dysfunction in the setting of HIV/AIDS.T-Cell Cytokines as Predictive Markers of the Risk of Allograft Rejection.Cytokine-based immune monitoring.Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation.Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology ImmunosuppreShould IFN-γ, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study.Early non-invasive selection of patients at high risk of severe hepatitis C recurrence after liver transplantation.Proteomic analysis of the secretome of human umbilical vein endothelial cells using a combination of free-flow electrophoresis and nanoflow LC-MS/MS.Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil.Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir.Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study.Risk factors associated with high linezolid trough plasma concentrations.High expression of CD38, CD69, CD95 and CD154 biomarkers in cultured peripheral T lymphocytes correlates with an increased risk of acute rejection in liver allograft recipients.High proportion of CD95(+) and CD38(+) in cultured CD8(+) T cells predicts acute rejection and infection, respectively, in kidney recipients.Development and validation of a UHPLC diode array detector method for meropenem quantification in human plasma.Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy.Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.Is the intracellular ATP concentration of CD4+ T-Cells a predictive biomarker of immune status in stable transplant recipients?Human apo A-I and rat transferrin are the principal plasma proteins that bind wine catechins.Defining the initial doses of sirolimus and tacrolimus in the period immediately after renal transplantation.Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil.New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations.Intracellular IFN-γ and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients.Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation.Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts.Determination of atorvastatin and its metabolite ortho-hydroxyatorvastatin in human plasma by on-line anion-exchange solid-phase extraction and liquid chromatography tandem mass spectrometry.The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus.Effects of cyclosporine, tacrolimus and sirolimus on vascular changes related to immune response.Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency.Steroids and living liver donation increase tacrolimus blood levels in living donor liver transplantation.
P50
Q33852812-02EF106A-10AD-4D45-9697-5D4839A7103EQ37418402-406D2708-A40B-4DC1-8E80-637E0DC544BFQ37811401-A2143894-2B54-4156-8DAF-E70D4A2AA9FAQ37824525-ED8D3DB8-5A07-4410-8D58-FE9D2C0CBFAEQ37830308-3E0488AC-87D8-438F-BB24-6444712CB66DQ38006196-D1E8424C-0BCE-4E04-B4F5-8207459B0A8EQ38007766-BD11EF57-681F-4EC4-929B-7C5B9EF12863Q38019428-2A8AFF77-3D1A-4D23-AE01-20989ABAEEE1Q38601427-7B760335-E0CC-4792-8129-454358F07303Q38708292-BC3D36D5-BA14-4BCA-B84A-40FB5E2716B0Q38775258-80411C7E-AF49-4EBE-B7DE-A7603500B5AAQ38776986-FCC07B1B-73F8-4A6E-97BA-C3FE0B7BF2E0Q39149234-D15B7B08-45CC-41C8-B8F5-EE9BD6FB3AADQ39908420-5603DA6F-76B7-47ED-9CE5-8C4F228D18F8Q39941004-63820B34-7F6C-46F6-AA39-50CBB4541E93Q40312625-ECDF8C5C-A8E2-471F-8363-2DB6CBF02A62Q40426684-5F7958EE-53A9-4D98-88FA-C4465821E935Q40542223-A6A70C37-93E8-4A33-9CD2-DD8F6B744471Q40683242-33807B72-A38C-4644-82E8-1BD65C9DDD9BQ40803041-3A96BAAA-36C9-4C9A-9AE7-8F9738344865Q40831146-62E62DFC-D504-413D-9B81-68E695411CF9Q42201656-244428C7-606E-42BD-BC1C-AA0EDD3067A4Q42255205-1A5198DB-2487-4D3B-92CB-E20905E73128Q42837781-9EBE0FB8-40A8-4348-94E1-5661FD7425B8Q42914849-7460923D-6B35-4139-A1F6-64E076819A76Q43119565-55FFAD63-421B-437B-AC0F-2E3B26ACE660Q43294957-966A1A08-3EE1-4A3F-A416-260F22BBE3F3Q43962474-4FA2CC4B-8EE3-4A8C-8E39-AD9FFCC5EDC1Q44577536-BB0C58B8-5CB7-4DD2-895D-212EFBEB499DQ44631878-293894C2-B43B-470B-99F0-328CDB72EDD4Q44812512-892B543D-E177-444F-B9CD-138427CC4B40Q44957569-A3F6CF1A-DCB6-48B4-9571-6196A2BEA29DQ44989307-AF8A9AA5-0DA5-439D-BF33-4E649B052977Q45153755-975AAE78-B2E8-43D1-B141-90D612D18880Q45977452-A4A1455B-8A45-4BC0-8888-A756BC651D8AQ46055999-4BC8FE8B-540D-436B-9A56-98F810AB5D8AQ46413360-52E7A278-A6F7-490F-89F7-0EA5C0C76F05Q46675318-B0131F91-8CF6-45F2-BA58-872C93D1D9FEQ46873870-E1F73475-ABEA-4E79-9223-EC3119A87530Q46873968-41697E87-CCD0-49CB-A136-3DEE2DF08021
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Mercè Brunet
@ast
Mercè Brunet
@en
Mercè Brunet
@es
Mercè Brunet
@nl
Mercè Brunet
@sl
type
label
Mercè Brunet
@ast
Mercè Brunet
@en
Mercè Brunet
@es
Mercè Brunet
@nl
Mercè Brunet
@sl
altLabel
brunet mercè
@en
mercedes brunet
@en
mercè brunet serra
@en
prefLabel
Mercè Brunet
@ast
Mercè Brunet
@en
Mercè Brunet
@es
Mercè Brunet
@nl
Mercè Brunet
@sl
P106
P1153
15839190700
P21
P214
1827156075616953980005
P31
P496
0000-0002-7154-916X
P7859
viaf-1827156075616953980005